Previously, synthetic lethality between the DNA repair proteins Poly(ADP-Ribose) Polymerase 1 (PARP1) and Breast cancer type 1 (BRCA1) resulted in the development of an anti-cancer drug, olaparib [44]. This evidence concerns the gene BRCA1 and cancer.